Celldex touted what it called the "consistent, impressive story" of its cancer vaccine Rintega this week as it released positive long-term survival data.
Médecins Sans Frontières, a global charity and frequent pharma critic, has initiated a worldwide petition calling for Pfizer and GlaxoSmithKline to reduce the prices of their pneumonia vaccines to $5 per child--for all three doses--in emerging markets and for humanitarian organizations. Read more >>
This week at the World Vaccines Congress in Spain, Sanofi Pasteur announced that in collaboration with the University of Georgia it has developed a candidate flu vaccine through genetic sequencing of many flu viruses. The vaccine, dubbed Cobra, is designed to protect against multiple strains over several years using common sequences the strains share. Read more >>
POPULAR COMMENT THREADS
The FDA has expanded the indication of Emergent BioSolutions' BioThrax anthrax vaccine for use in adults aged 18 to 65 in conjunction with antibiotic treatment, following confirmed or suspected exposure to Bacillus anthracis.
While working to catch up with other vaccine developers in the race for a respiratory syncytial virus (RSV) vaccine, San Francisco-based Vaxart this week unveiled data demonstrating its candidate's ability to create a "substantial" immune response in a preclinical challenge model.
Sanofi is the furthest along in the race for a dengue vaccine, expecting its first license to market its jab by the end of the year. But this doesn't mean others aren't trying to tackle the mosquito-borne disease: SUNY Upstate Medical University announced on Monday a $12 million partnership with the U.S. Army to develop a dengue vaccine.
In the latest of a string a partnerships forged this year, Daiichi Sankyo is teaming up with Sanofi's Japanese unit to launch Squarekids subcutaneous injection syringe, a tetravalent vaccine for the prevention of diphtheria, pertussis, tetanus and polio.
Brigham Young University researchers have developed a "just add water" method to expedite vaccine production in the face of new viruses. The process involves creating vaccine production machinery en masse and then freeze-drying it and stockpiling it in different locations.
GlaxoSmithKline's experimental Ebola jab, which was taken to Phase I in the U.S. and Mali last October, was well-tolerated and elicited strong immune responses in adults.
From Our Sister Sites
Siemens plans 7,000+ layoffs after disappointing healthcare performance Following a 13% reduction in profit at Siemens Healthcare during the previous quarter, the conglomerate is reportedly planning...
Sweden's Lund University is forming a med tech accelerator with an emphasis on digital health.